0001493152-21-006062.txt : 20210316 0001493152-21-006062.hdr.sgml : 20210316 20210316080037 ACCESSION NUMBER: 0001493152-21-006062 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20210131 FILED AS OF DATE: 20210316 DATE AS OF CHANGE: 20210316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advaxis, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 21743671 BUSINESS ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON, STATE: NJ ZIP: 08540 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON, STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2021

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 001-36138

ADVAXIS, INC.

(Exact name of registrant as specified in its charter)

Delaware		02-0563870
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

305 College Road East, Princeton, NJ		08540
(Address of principal executive offices)		(Zip Code)

(609) 452-9813

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ADXS	Nasdaq Capital Market
Preferred Share Purchase Rights	-	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has fled all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	[ ]	Accelerated Filer	[ ]
Non-accelerated Filer	[X]	Smaller Reporting Company	[X]
Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The number of shares of the registrant’s Common Stock, $0.001 par value, outstanding as of March 8, 2021 was 119,466,620.

TABLE OF CONTENTS

		Page No.

PART I	FINANCIAL INFORMATION	5

Item 1.	Financial Statements (unaudited)	5

	Condensed Balance Sheets	5

	Condensed Statements of Operations	6

	Condensed Statements of Cash Flows	7

	Notes to the Condensed Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II	OTHER INFORMATION	25

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 6.	Exhibits	25

SIGNATURES		26

CAUTIONARY NOTE REGARDING FORWARD LOOKING-STATEMENTS

This quarterly report on Form 10-Q (“Form 10-Q”) of Advaxis, Inc. (the “Company”) includes statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by the use of such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or the negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, our available cash, liquidity, prospects, growth and strategies, impacts of the ongoing coronavirus (COVID-19) pandemic, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect our industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to the occurrence and timing of events or circumstances, many of which are beyond the control of the Company As a result of these, we cannot assure you that the forward-looking statements in this Form 10-Q will prove to be accurate. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, they may not be predictive of results or developments in future periods.

Some of the material factors that we believe could cause actual results to differ from those anticipated or predicted include:

	●	the success and timing of our clinical trials, including patient accrual;

	●	our ability to obtain and maintain regulatory approval or reimbursement of our product candidates for marketing;

	●	our ability to obtain the appropriate labeling of our products under any regulatory approval;

	●	our ability to develop and commercialize our products;
	●	potential effects of the COVID-19 pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted prior to the macroeconomic effects of the COVID-19 pandemic;

	●	the successful development and implementation of our sales and marketing campaigns;

	●	the change of key scientific or management personnel;

	●	the size and growth of the potential markets for our product candidates and our ability to serve those markets;

	●	our ability to successfully compete in the potential markets for our product candidates, if commercialized;

	●	regulatory developments in the United States and other countries;

	●	the rate and degree of market acceptance of any of our product candidates;

	●	new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements;

	●	market conditions in the pharmaceutical and biotechnology sectors;

	●	our available cash;

	●	the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;

	●	our ability to obtain additional funding;

	●	our ability to obtain and maintain intellectual property protection for our product candidates;

	●	the success and timing of our preclinical studies, including IND enabling studies;

	●	the ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;

	●	our ability to obtain and maintain approval of our product candidates for trial initiation;

	●	our ability to manufacture and the performance of third-party manufacturers;

	●	our ability to identify license and collaboration partners and to maintain existing relationships;

	●	the performance of our clinical research organizations, clinical trial sponsors, clinical trial investigators and collaboration partners for any clinical trials we conduct;

	●	any outcomes from our review of strategic transactions;

	●	our ability to successfully implement our strategy; and

	●	the factors described in the “Risk Factors” section of the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2020 (the “2020 Annual Report on Form 10-K”), as updated and amended in other filings by the Company with the Securities and Exchange Commission (the “SEC”).

You should also read carefully the factors described in the “Risk Factors” section of the 2020 Annual Report on Form 10-K. Any forward-looking statements that we make in this Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 10-Q except as required by the federal securities laws.

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ADVAXIS, INC.

CONDENSED BALANCE SHEETS

(In thousands, except share and per share data)

	January 31, 2021			October 31, 2020
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	33,318		$	25,178
Deferred expenses		1,602			1,808
Prepaid expenses and other current assets		608			865
Total current assets		35,528			27,851

Property and equipment (net of accumulated depreciation)		2,189			2,393
Intangible assets (net of accumulated amortization)		3,404			3,261
Operating right-of-use asset (net of accumulated amortization)		4,644			4,839
Other assets		182			182
Total assets	$	45,947		$	38,526

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	399		$	410
Accrued expenses		2,142			1,737
Common stock warrant liability		44			17
Current portion of operating lease liability		992			962
Deferred revenue		-			165
Total current liabilities		3,577			3,291

Operating lease liability, net of current portion		4,795			5,055
Total liabilities		8,372			8,346

Commitments and contingencies – Note 9

Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2021 and October 31, 2020; Liquidation preference of $0 at January 31, 2021 and October 31, 2020		-			-
Common stock - $0.001 par value; 170,000,000 shares authorized, 116,130,688 and 78,074,023 shares issued and outstanding at January 31, 2021 and October 31, 2020, respectively		116			78
Additional paid-in capital		452,174			440,840
Accumulated deficit		(414,715	)		(410,738	)
Total stockholders’ equity		37,575			30,180
Total liabilities and stockholders’ equity	$	45,947		$	38,526

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

	Three Months Ended January 31,
	2021			2020

Revenue	$	1,615		$	3

Operating expenses:
Research and development expenses		2,570			4,859
General and administrative expenses		3,008			3,030
Total operating expenses		5,578			7,889

Loss from operations		(3,963	)		(7,886	)

Other income (expense):
Interest income, net		1			66
Net changes in fair value of derivative liabilities		(27	)		(37	)
Other income		12			-
Net loss before benefit for income taxes		(3,977	)		(7,857	)

Income tax expense		-			-

Net loss	$	(3,977	)	$	(7,857	)

Net loss per common share, basic and diluted	$	(0.05	)	$	(0.15	)

Weighted average number of common shares outstanding, basic and diluted		83,943,982			51,747,246

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

	Three Months Ended January 31,
	2021			2020

OPERATING ACTIVITIES
Net loss	$	(3,977	)	$	(7,857	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation		236			242
Loss on change in value of warrants		27			37
Loss on disposal of property and equipment		12			-
Abandonment of intangible assets		-			232
Depreciation expense		192			229
Amortization expense of intangible assets		67			91
Amortization of right-of-use asset		195			181
Change in operating assets and liabilities:
Prepaid expenses and other current assets		463			789
Other assets		-			1
Accounts payable and accrued expenses		394			(1,462	)
Deferred revenue		(165	)		-
Operating lease liabilities		(230	)		(191	)
Net cash used in operating activities		(2,786	)		(7,708	)

INVESTING ACTIVITIES
Cost of intangible assets		(210	)		(238	)
Net cash used in investing activities		(210	)		(238	)

FINANCING ACTIVITIES
Net proceeds of issuance of common stock		8,550			9,737
Warrant exercise		2,586			-
Proceeds from employee stock purchase plan		-			2
Net cash provided by financing activities		11,136			9,739

Net increase in cash and cash equivalents		8,140			1,793
Cash and cash equivalents at beginning of period		25,178			32,363
Cash and cash equivalents at end of period	$	33,318		$	34,156

SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes	$	-		$	-

SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Warrant liability reclassified into equity		-			2
Amounts accrued for offering costs		-			109

The accompanying notes should be read in conjunction with the financial statements.

ADVAXIS, INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm Technology^TM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

Liquidity and Capital Resources

Liquidity and Management’s Plans

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

As of January 31, 2021, the Company had approximately $33.3 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least March 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including an at-the-market (“ATM”) program through A.G.P./Alliance Global Partners and an equity line financing arrangement with Lincoln Park Capital. Pursuant to these warrant exercises, the Company received aggregate proceeds of about $2.6 million which were payable upon exercise. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing.

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of January 31, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-KA filed on February 26, 2021.

Net Income (Loss) per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of January 31, 2021 and 2020. As of January 31, 2021 and 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.

	As of January 31,
	2021		2020
Warrants		8,014,220		5,405,726
Stock options		1,047,377		553,446
Restricted stock units		5,556		11,644
Total		9,067,153		5,970,816

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Leasehold improvements	$	2,335		$	2,335
Laboratory equipment		1,131			1,218
Furniture and fixtures		744			744
Computer equipment		409			409
Construction in progress		19			19
Total property and equipment		4,638			4,725
Accumulated depreciation and amortization		(2,449	)		(2,332	)
Net property and equipment	$	2,189		$	2,393

Depreciation expense for the three months ended January 31, 2021 and 2020 was $0.2 million.

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Patents	$	4,689		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,583			5,373
Accumulated amortization		(2,179	)		(2,112	)
Intangible assets	$	3,404		$	3,261

The expiration dates of the existing patents range from 2021 to 2040 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of $0 million and $0.3 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $ 67 thousand and $0.1 million for each of the three months ended January 31, 2021 and 2020, respectively.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

As of January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	205
2022		273
2023		273
2024		273
2025		273
Thereafter		2,107
Total	$	3,404

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	January 31, 2021		October 31, 2020

Salaries and other compensation	$	496	$	737
Vendors		1,414		671
Professional fees		232		329
Total accrued expenses	$	2,142	$	1,737

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of January 31, 2021, there were outstanding warrants to purchase 8,341,558 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,863	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		7,943,332	November 2025	November 2020 Public Offering
	Grand Total		8,341,558

As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

A summary of warrant activity for the quarter ended January 31, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		15,333,332			0.35		4.82
Exercised		(7,390,000	)		0.35
Outstanding and exercisable warrants at January 31, 2021		8,341,558		$	0.45		4.76	$	3,048,937

As of January 31, 2021, the Company had 8,270,695 of its total 8,341,558 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the condensed balance sheets.

Warrant Liability

As of January 31, 2021, the Company had 70,863 of its total 8,341,558 outstanding warrants from September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

In measuring the warrant liability at January 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	January 31, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.73		$	0.34
Expected Term		3.61 years			3.87 years
Volatility %		114	%		106	%
Risk Free Rate		0.20	%		0.29	%

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended January 31,
	2021		2020
Research and development	$	57	$	91
General and administrative		179		151
Total	$	236	$	242

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2021 is as follows:

	Number of RSUs		Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556	$	24.32
Vested		-
Cancelled		-
Balance at January 31, 2021		5,556	$	24.32

As of January 31, 2021, there was approximately $30,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 0.22 years.

As of January 31, 2021, the aggregate intrinsic value of non-vested RSU’s was approximately $4,100.

Employee Stock Awards

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 0 shares and 2,957 shares during the three months ended January 31, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the three months ended January 31, 2021 and 2020 was approximately $0 and $56,000, respectively.

Stock Options

A summary of changes in the stock option plan for the three months ended January 31, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Cancelled or expired		(14,391	)		21.49
Outstanding as of January 31, 2021		1,047,377		$	32.02		7.89	$	143
Vested and exercisable at January 31, 2021		313,268		$	103.55		4.72	$	18

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	0.30-$10.00		793,412		9.20	$	3.52		83,201		8.30	$	3.52
$	10.01-$100.00		91,727		6.93	$	29.17		67,829		6.83	$	31.01
$	100.01-$200.00		92,847		2.51	$	166.04		92,847		2.51	$	166.04
$	200.01-$277.50		69,391		1.33	$	210.79		69,391		1.33	$	210.79

During the three months end January 31, 2021, the Company granted options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39.

Total compensation cost related to the Company’s outstanding stock options, recognized in the condensed statements of operations for the three months ended January 31, 2021 and 2020 was approximately $0.2 million.

As of January 31, 2021, there was approximately $0.4 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.54 years.

As of January 31, 2021, the aggregate intrinsic value of vested and exercisable options was $143 thousand and the aggregate intrinsic value of non-vested options was approximately $18 thousand.

In determining the fair value of the stock options granted during the three months ended January 31, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Three Months Ended January 31, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

Employee Stock Purchase Plan

During the three months ended January 31, 2021 and 2020, the Company issued 0 and 5,555 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

10. LEASES

Operating Leases

The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the condensed balance sheet.

The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:

	●	As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease.

	●	Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.

	●	Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.

	●	Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability.

Supplemental balance sheet information related to leases as of January 31, 2021 is as follows (in thousands):

Operating leases:
Operating lease right-of-use assets	$	4,644

Operating lease liability	$	992
Operating lease liability, net of current portion		4,795
Total operating lease liabilities	$	5,787

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended January 31, 2021		For the Three Months Ended January 31, 2020
Operating lease cost	General and administrative		290		290
Short-term lease cost	General and administrative		-		85
Variable lease cost	General and administrative	$	437		141
Total lease expense		$	727		516

Other information related to leases where the Company is the lessee is as follows:

	For the Three Months Ended January 31, 2021
Weighted-average remaining lease term		4.8 years
Weighted-average discount rate		6.5	%

Supplemental cash flow information related to operating leases was as follows:

		For the Three Months Ended January 31, 2021				For the Three Months Ended January 31, 2020
Cash paid for operating lease liabilities		$	324				300

Future minimum lease payments under non-cancellable leases as of January 31, 2021 is as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	1,369
2022		1,395
2023		1,419
2024		1,444
2025		120
Thereafter		993
Total minimum lease payments		6,740
Less: Imputed interest		(953	)
Total	$	5,787

Under ASC 842, future minimum payments under the Company’s operating lease were as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	993
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total	$	6,740

Under ASC 842, rent expense for each of the three months ended January 31, 2021 and 2020 was approximately $0.3 million.

11. STOCKHOLDERS’ EQUITY

Public Offerings

In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.

During the three months ended January 31, 2020, warrant holders from the Company’s November 2020 offering exercised 7,390,000 warrants in exchange for 7,390,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of about $2.6 million which were payable upon exercise.

A summary of the changes in stockholders’ equity for the three months ended January 31, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575

12. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2021 and October 31, 2020 (in thousands):

January 31, 2021		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024			-				-			$	44			$	44

October 31, 2020		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024			-				-			$	17			$	17

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Three Months Ended January 31, 2021
Beginning balance	$	17
Warrant exercises		-
Change in fair value		27
Ending Balance	$	44

13. Subsequent Events

In February 2021, warrant holders exercised about 3.3 million warrants from the Company’s November 2020’s offering. The Company received aggregate proceeds of about $1.2 million from these exercises.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results indicated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in Part I Item 1A. “Risk Factors” in our 2020 Annual Report on Form 10-K, below in Part II Item 1A. “Risk Factors” of this Form 10-Q. and in the “Cautionary Note Regarding Forward-Looking Statements” set forth at the beginning of this report.

You should read the following discussion and analysis in conjunction with the unaudited financial statements, and the related footnotes thereto, appearing elsewhere in this Form 10-Q, and in conjunction with management’s discussion and analysis and the audited financial statements included in our Annual Report on Form 10-K. In addition, we intend to use our media and investor relations website (www.advaxis.com/investor-relations), SEC filings, press releases, public conference calls and webcasts to communicate with the public about Advaxis, its services and other issues.

Overview

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.

The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates (i.e., ADXS-PSA and ADXS-503) have the potential to optimize checkpoint performance, while having a generally well-tolerated safety profile, and most of our product candidates have an expected low cost of goods. A new Investigator-Sponsored-Study with our FDA-approved IND is expected to start with ADXS-504-HOT construct in biochemically recurrent prostate cancer patients at a leading US Medical Institution in the first half of 2021.

Advaxis is currently winding down clinical studies of Lm Technology immunotherapies in three program areas:

	●	Human Papilloma Virus (“HPV”)-associated cancers
	●	Personalized neoantigen-directed therapies
	●	Human epidermal growth factor receptor-2 (HER-2) associated cancers

All these clinical program areas are anchored in the Company’s Lm Technology^TM, a unique platform designed for its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinical studies of Lm Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies, LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of AXAL in Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.

Recent Developments

On March 11, 2020, the World Health Organization declared the coronavirus (COVID-19) to be a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19. The pandemic has resulted in government-imposed quarantines, travel restrictions, business and school closures and other public health safety measures, many of which remain in effect to varying degrees. We continue to monitor the COVID-19 pandemic and take steps intended to mitigate the potential risks to our workforce and our operations. The COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Nonetheless, thus far, the COVID-19 pandemic has not had a significant impact on our business or results of operations. However, we remain in contact with the clinical sites in our study and are in discussion with additional sites to combat any potential impact in enrollment. We are unable to determine or predict the extent, duration or scope of the overall impact of the COVID-19 pandemic on our business, operations, financial condition or liquidity.

Strategic Transactions

As a matter of course, we are reviewing strategic transactions and alternatives and there can be no assurance that we will be successful in identifying or completing any strategic transactions, that any such strategic transaction will result in additional value for our stockholders or that the process will not have an adverse impact on our business. These transactions could include, but are not limited to, collaboration agreements, co-development agreements, strategic mergers, reverse mergers, the issuance or buyback of public shares, or the purchase or sale of specific assets, in addition to other potential actions aimed at increasing stockholder value. There can be no assurance that the review of strategic transactions will result in the identification or consummation of any transaction. Our Board of Directors may also determine that our most effective strategy is to continue to effectuate our current business plan. Any potential transaction would be dependent upon a number of factors that may be beyond our control, including, but not limited to, market conditions, industry trends, the interest of third parties in our business and the availability of financing to potential buyers on reasonable terms. No decision has been made with respect to any transaction.

Results of Operations for the Three Months Ended January 31, 2021 and 2020

Revenue

Revenue increased approximately $1,612 thousand to $1,615 thousand for the three months ended January 31, 2021 compared to $3 thousand for the three months ended January 31, 2020. In the current period, we recognized royalty payments from OST.

Research and Development Expenses

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the three months ended January 31, 2021 and January 31, 2020 were categorized as follows (in thousands):

	Three Months Ended January 31,				Increase (Decrease)
	2021		2020		$			%

Hotspot/Off-the-Shelf therapies	$	1,200	$	553	$	647			117	%
Prostate cancer		42		378		(336	)		(89	)%
HPV-associated cancers		531		1,735		(1,204	)		(69	)%
Personalized neoantigen-directed therapies		132		350		(218	)		(62	)%
Other expenses		665		1,843		(1,178	)		(64	)%
Total research & development expense	$	2,570	$	4,859	$	(2,289	)		(47	)%

Stock-based compensation expense included in research and development expense	$	57	$	91	$	(34	)		(37	)%

General and Administrative Expenses

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the three months ended January 31, 2021 and January 31, 2020 were as follows (in thousands):

	Three Months Ended January 31,				Increase (Decrease)
	2021		2020		$			%

General and administrative expense	$	3,008	$	3,030	$	(22	)		(1	)%

Stock-based compensation expense included in general and administrative expense	$	179	$	151	$	28			19	%

General and administrative expenses for the three months ended January 31, 2021 decreased approximately $22 thousand, or 1%, compared to the same period in 2020. The decrease was immaterial.

Changes in Fair Values

For the three months ended January 31, 2021, we recorded non-cash loss from changes in the fair value of the warrant liability of approximately $27 thousand. The decrease in the fair value of liability warrants resulted from a decrease in our share price from $0.34 at October 31, 2020 to $0.73 at January 31, 2021.

For the three months ended January 31, 2020, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $37 thousand. The increase in the fair value of liability warrants resulted from an increase in our share price from $0.32 at October 31, 2019 to $0.86 at January 31, 2020

Liquidity and Capital Resources

Management’s Plans

Similar to other development stage biotechnology companies, our products that are being developed have not generated significant revenue. As a result, we have historically suffered recurring losses and we have required significant cash resources to execute our business plans. These losses are expected to continue for the foreseeable future.

Historically, the Company’s major sources of cash have comprised proceeds from various public and private offerings of its securities (including common stock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interest income. From October 2013 through January 31, 2021, the Company raised approximately $317.9 million in gross proceeds ($8.5 million during the three months ended January 31, 2021) from various public and private offerings of our common stock. The Company has sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future. As of January 31, 2021 and October 31, 2020, the Company had an accumulated deficit of approximately $414.7 million and $410.7 million, respectively, and stockholders’ equity of approximately $37.6 million and $30.2 million, respectively.

The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively affect the Company’s business, financial condition, and access to sources of liquidity. As of January 31, 2021, the Company had approximately $33.3 million in cash and cash equivalents. The actual amount of cash that the Company will need to continue operating is subject to many factors. The Company based this estimate on assumptions that may prove to be wrong, and we could use available capital resources sooner than currently expected.

The Company recognizes that it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to it or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

On May 8, 2020, the Company entered into a sales agreement related to an at-the-market equity offering program pursuant to which the Company may sell, from time to time, common stock with an aggregate offering price of up to $40 million through A.G.P./Alliance Global Partners, as sales agent, for general corporate purposes.

On July 30, 2020, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Over the 36-month term of the purchase agreement, the Company has the right, but not the obligation, from time to time, in its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to an aggregate amount of $20,000,000 of its common stock, subject to certain limitations.

Due to the current state of the Company’s stock price and general market conditions, these programs have not been utilized to their fullest extent, thereby resulting in lower capital availability than anticipated. Management’s plans to mitigate an expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategic or financing investors.

Cash Flows

Operating Activities

Net cash used in operating activities includes reduced spending associated with our clinical trial programs and general and administrative activities. Net cash used in operating activities was approximately $2.8 million for the three months ended January 31, 2021, compared to $7.7 million for the three months ended January 31, 2020. The decrease was due to measures to control costs for non-essential items in areas that did not support our strategic direction, and as a result, we have continued to reduce non-strategic operating expenditures over the past several quarters.

Investing Activities

Net cash used in investing activities was approximately $0.2 million for the three months ended January 31, 2021 and 2020 for intangible assets.

Financing Activities

Net cash provided by financing activities was approximately $11.1 million for the three months ended January 31, 2021, as compared to $9.7 million for the three months ended January 31, 2020. On November 27, 2020, the Company completed an underwritten public offering of 26,666,666 shares of common stock and common stock warrants to purchase up to 13,333,333 shares of common stock (the “November 2020 Offering”). On November 24, 2020, the underwriters notified us that they had exercised their option to purchase an additional 3,999,999 shares of common stock and 1,999,999 warrants in full. After giving effect to the full exercise of the underwriters’ option, we issued and sold an aggregate 30,666,665 shares of common stock and warrants to purchase up to 15,333,332 shares of common stock. We received gross proceeds of approximately $9.2 million, before deducting the underwriting discounts and commissions and fees and expenses payable by us in connection with the November 2020 Offering. In January 2020, we completed a public offering of 10,000,000 shares of our common stock, which resulted in net proceeds of approximately $9.7 million.

Off-Balance Sheet Arrangements

As of January 31, 2021, we had no off-balance sheet arrangements.

Critical Accounting Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

	●	it requires assumptions to be made that were uncertain at the time the estimate was made, and

	●	changes in the estimate or different estimates that could have been selected could have a material impact in our results of operations or financial condition.

While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material. The most significant estimates impact the following transactions or account balances: stock compensation, warrant liability valuation and impairment of intangibles.

See Note 2 to our condensed financial statements for a discussion of our significant accounting policies.

Recently Issued Accounting Standards Not Yet Effective or Adopted

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

At January 31, 2021, we had approximately $33.3 million in cash and cash equivalents, which consisted primarily of bank deposits and money market funds. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy and achieve our investment objectives. We typically invest in highly-rated securities, and our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.

We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and interim principal financial officer of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). Based upon this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the quarter ended January 31, 2021, there were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Limitations on Effectiveness of Controls

Our management, including our Principal Executive, Financial and Accounting Officers, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

Our business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our 2020 Annual Report on Form 10-K should be carefully considered. There has been no material change in this information. The risks described in the 2020 Annual Report on Form 10-K, and the information in the section of this Form 10-Q entitled “Cautionary Note Regarding Forward Looking Statements” are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations.

Item 6. Exhibits

Exhibit No.		Description

3.1		Second Amended and Restated By-Laws of Advaxis, Inc., incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 5, 2021.

31.1*		Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL INSTANCE DOCUMENT

101.SCH		XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

101.CAL		XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

101.DEF		XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

101.LAB		XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

101.PRE		XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

* Filed herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Corporation has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 16, 2021

	ADVAXIS, INC.

	By:	/s/ Igor Gitelman
	Name:	Igor Gitelman
	Title:	Chief Accounting Officer, VP of Finance

	By:	/s/ Kenneth Berlin
	Name:	Kenneth Berlin
	Title:	President, Chief Executive Officer and Interim Chief Financial Officer

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18.U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

I, Kenneth Berlin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended January 31, 2021 of Advaxis, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 16, 2021

By:	/s/ Kenneth Berlin
Name:	Kenneth Berlin
Title:	President & Chief Executive Officer and Interim Chief Financial Officer

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18. U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

I, Kenneth Berlin, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended January 31, 2021 of Advaxis, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

March 16, 2021

By:	/s/ Kenneth Berlin
Name:	Kenneth Berlin
Title:	President., Chief Executive Officer and Interim Chief Financial Officer

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended January 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Executive Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: March 16, 2021	By:	/s/ Kenneth Berlin
	Name:	Kenneth Berlin
	Title:	President., Chief Executive Officer and Interim Chief Financial Officer

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended January 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: March 16, 2021	By:	/s/ Kenneth Berlin
	Name:	Kenneth Berlin
	Title:	President, Chief Executive Officer and Interim Chief Financial Officer

EX-101.INS 6 adxs-20200131.xml XBRL INSTANCE FILE 0001100397 2020-11-01 2021-01-31 0001100397 2020-10-31 0001100397 2021-01-31 0001100397 us-gaap:FairValueInputsLevel1Member 2020-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2020-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2020-10-31 0001100397 srt:MinimumMember 2020-10-31 0001100397 srt:MaximumMember 2020-10-31 0001100397 ADXS:EquityWarrantsMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2019-11-01 2020-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2019-11-01 2020-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2019-11-01 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2020-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-10-31 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2020-10-31 0001100397 us-gaap:IPOMember 2020-11-01 2020-11-30 0001100397 us-gaap:IPOMember 2020-11-30 0001100397 us-gaap:PrivatePlacementMember 2020-11-30 0001100397 us-gaap:FairValueInputsLevel1Member 2021-01-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-01-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-01-31 0001100397 2020-11-01 2020-11-30 0001100397 2019-11-01 2020-01-31 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2020-04-29 2020-04-30 0001100397 2020-01-31 0001100397 2021-03-08 0001100397 2019-10-31 0001100397 ADXS:OSTherapiesLLCMember ADXS:MileStoneSetForthInTheLicenceAgreementMember 2021-01-01 2021-01-31 0001100397 ADXS:OSTherapiesLLCMember ADXS:MileStoneSetForthInTheLicenceAgreementMember 2020-12-01 2020-12-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-01-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2019-11-01 2020-01-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2019-10-31 0001100397 us-gaap:PreferredStockMember 2020-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2019-10-31 0001100397 us-gaap:CommonStockMember 2020-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2019-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-01-31 0001100397 us-gaap:PreferredStockMember 2019-11-01 2020-01-31 0001100397 us-gaap:CommonStockMember 2019-11-01 2020-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0001100397 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember 2020-11-01 2021-01-31 0001100397 ADXS:WarrantLiabilityMember 2021-01-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-01-31 0001100397 us-gaap:WarrantMember 2019-11-01 2020-01-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-01-31 0001100397 ADXS:StockOptionsMember 2020-11-01 2021-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2020-11-01 2021-01-31 0001100397 us-gaap:WarrantMember 2019-11-01 2020-01-31 0001100397 ADXS:StockOptionsMember 2019-11-01 2020-01-31 0001100397 ADXS:RestrictedStockUnitsMember 2019-11-01 2020-01-31 0001100397 srt:MinimumMember 2021-01-31 0001100397 srt:MaximumMember 2021-01-31 0001100397 ADXS:EquityWarrantsMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember srt:MaximumMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember srt:MinimumMember 2021-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-01-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-01-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-01-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-01-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2021-01-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-01-31 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0001100397 us-gaap:RestrictedStockUnitsRSUMember 2020-11-01 2021-01-31 0001100397 ADXS:EmployeeStockAwardsMember 2020-11-01 2021-01-31 0001100397 ADXS:EmployeeStockAwardsMember 2019-11-01 2020-01-31 0001100397 ADXS:TwoThousandEighteenEmployeeStockPurchasePlanMember 2020-11-01 2021-01-31 0001100397 ADXS:TwoThousandEighteenEmployeeStockPurchasePlanMember 2019-11-01 2020-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-01-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-01-31 0001100397 us-gaap:SubsequentEventMember ADXS:NovemberTwoThousandTwentyofferingMember 2021-02-28 0001100397 us-gaap:SubsequentEventMember ADXS:NovemberTwoThousandTwentyofferingMember 2021-02-27 2021-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

170000000

236000

242000

179000

151000

56000

57000

91000

Advaxis, Inc. 0001100397 10-Q 2021-01-31 false --10-31

0.001

5000000

0.001

78074023

116130688

78074023

116130688

0.372

281.25

0.37

281.25

0.372

0.35

0.30

281.25

22.50

0.30

281.25

0.30

2.80

0.35

30180000

37575000

41548000

39531000

50000

60000

423750000

433614000

-384269000

-392126000

78000

116000

440840000

452174000

-410738000

-414715000

Q1 true false 17000 44000 17000 17000 44000 44000

27000

1615000

3000

25000

8500000

2600000

2957

5555

-3977000

-7857000

-3977000

-7857000

25178000

33318000

34156000

32363000

2000

8550000

9737000

2000

8550000

9628000

31000

8519000

10000

9618000

30666665

10000000

2586000 2000 7000 2579000 2000 Yes false Yes

4839000

4644000

962000

992000

Non-accelerated Filer 2021

398226

8341558

327363

70863

327338

70863

15333332

7390000

70863

8270695

70863

327338

7943332

3300000

30666665

2337500

165000

2025-11-30

182000

300000

5787000

P4Y9M18D

0.065

324000

300000

953000

120000

6740000

0.30

9200000

38526000

45947000

-410738000

-414715000

440840000

452174000

78000

116000

8346000

8372000

5055000

4795000

3291000

3577000

1737000

2142000

410000

399000

38526000

45947000

182000

3261000

3404000

2393000

2189000

27851000

35528000

865000

608000

1808000

1602000

25178000

33318000

83943982

51747246

-0.05

-0.15

-3977000

-7857000

-27000

-37000

1000

66000

-3963000

-7886000

5578000

7889000

3008000

3030000

2570000

4859000

8140000

1793000

11136000

9739000

2000

2586000

1200000

-210000

-238000

210000

238000

-2786000

-7708000

-230000 -191000

-165000

394000

-1462000

-1000

-463000

-789000

195000

181000

67000

91000

192000

229000

232000

-12000

109000

12000

The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.

290000

85000

437000

141000

727000

516000

1369000

1395000

1419000

1444000

120000

993000

6740000

993000

1369000

1395000

1419000

1444000

50201671

60236599

78074023

116130688

236000

242000

236000

242000

7390000 26416

0.34

0.73

9067153

5970816

343838

8014220

1047377

5556

5405726

553446

11644

2335000

1218000

1131000

744000

409000

19000

4725000

4638000

2332000

2449000

The expiration dates of the existing patents range from 2021 to 2040.

4479000

4689000

777000

117000 117000

5373000

5583000

2112000

2179000

205000

273000

2107000

3404000

737000

496000

671000

1414000

329000

232000

2024-07-31

2024-09-30

2024-07-31

2024-09-30

2025-11-30

July 2019 Public Offering Other Warrants September 2018 Public Offering Other warrants September 2018 Public Offering July 2019 Public Offering November 2020 Public Offering

398226

8341558

15333332

7390000

0.08 0.45 0.35 0.35 P3Y9M3D P4Y9M25D P4Y9M3D 110640000 3048937000

P3Y10M14D

P3Y7M10D

106

0.29

114

0.20

400000

30000

P1Y6M14D

P0Y2M19D

4100

50000

P8Y0M15D

P3Y

33.43

0.39

200000

143000

4000

18000

5556

24.32

1011768

1047377

14391

313268

0.39

21.49

103.55

P7Y10M21D

P4Y8M19D

18000

0.30

10.01

100.01

200.01

10.00

100.00

200.00

277.50

P8Y3M19D

P6Y9M29D

P2Y6M3D

P1Y3M29D

P6Y

1.0327

0.00

0.0053

273000

1. NATURE OF OPERATIONS   Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Attacking the tumor by generating a strong, cancer-specific T cell response; and</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.</td></tr> </table>   Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.   Liquidity and Capital Resources   Liquidity and Management’s Plans   Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.   As of January 31, 2021, the Company had approximately $33.3 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least March 2022, the actual amount of cash that it will need to operate is subject to many factors. Over the past year, the Company has taken steps to obtain additional financing, including an at-the-market (“ATM”) program through A.G.P./Alliance Global Partners and an equity line financing arrangement with Lincoln Park Capital. Pursuant to these warrant exercises, the Company received aggregate proceeds of about $2.6 million which were payable upon exercise. With these funds raised and a reduction in the operating expenses the Company believes that it has enough cash to fund its operations for one year from the date of filing.   The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

3. PROPERTY AND EQUIPMENT   Property and equipment, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Leasehold improvements</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Laboratory equipment</td> <td> </td> <td> </td> <td style="text-align: right">1,131</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Furniture and fixtures</td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer equipment</td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Construction in progress</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total property and equipment</td> <td> </td> <td> </td> <td style="text-align: right">4,638</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,725</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,449</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,332</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net property and equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,189</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the three months ended January 31, 2021 and 2020 was $0.2 million.

4. INTANGIBLE ASSETS   Intangible assets, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,689</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,479</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Licenses</td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Software</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total intangibles</td> <td> </td> <td> </td> <td style="text-align: right">5,583</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,373</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,179</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,404</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The expiration dates of the existing patents range from 2021 to 2040 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of $0 million and $0.3 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2021 and 2020, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated $ 67 thousand and $0.1 million for each of the three months ended January 31, 2021 and 2020, respectively.   Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company will likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.   As of January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fiscal year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">205</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,107</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,404</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

5. ACCRUED EXPENSES:   The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Salaries and other compensation</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">496</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">737</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vendors</td> <td> </td> <td> </td> <td style="text-align: right">1,414</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">671</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Professional fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">232</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">329</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,142</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY   Warrants   As of January 31, 2021, there were outstanding warrants to purchase 8,341,558 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares Underlying Warrants</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">281.25</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 28%">N/A</td> <td style="width: 1%"> </td> <td style="width: 23%">Other warrants</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,863</td> <td> </td> <td> </td> <td>July 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">2.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,338</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,943,332</td> <td> </td> <td> </td> <td>November 2025</td> <td> </td> <td>November 2020 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">Grand Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,341,558</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares Underlying Warrants</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">327,338</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 28%">July 2024</td> <td style="width: 1%"> </td> <td style="width: 23%">July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">281.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25</td> <td> </td> <td> </td> <td>N/A</td> <td> </td> <td>Other Warrants</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">0.372</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,863</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Grand Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">398,226</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   A summary of warrant activity for the quarter ended January 31, 2021 is as follows (in thousands, except share and per share data):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Outstanding and exercisable warrants at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">398,226</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">110,640</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">15,333,332</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.82</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,390,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.35</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding and exercisable warrants at January 31, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,341,558</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.76</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,048,937</td> <td> </td></tr> </table>   As of January 31, 2021, the Company had 8,270,695 of its total 8,341,558 outstanding warrants classified as equity (equity warrants). At October 31, 2020, the Company had 327,363 of its total 398,226 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the condensed balance sheets.   Warrant Liability   As of January 31, 2021, the Company had 70,863 of its total 8,341,558 outstanding warrants from September 2018 Public Offering classified as liabilities (liability warrants). At October 31, 2020, the Company had 70,863 of its total 398,226 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2021, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.30.  The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.   In measuring the warrant liability at January 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.37</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.73</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.34</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">3.61 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.87 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">114</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.20</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.29</td> <td>%</td></tr> </table>

7. SHARE BASED COMPENSATION   The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended January 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Research and development</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">57</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">91</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">179</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">151</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">236</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Restricted Stock Units (RSUs)   A summary of the Company’s RSU activity and related information for the three months ended January 31, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of RSUs</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Grant Date Fair Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">5,556</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">24.32</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,556</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">24.32</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of January 31, 2021, there was approximately $30,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 0.22 years.   As of January 31, 2021, the aggregate intrinsic value of non-vested RSU’s was approximately $4,100.   Employee Stock Awards   Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 0 shares and 2,957 shares during the three months ended January 31, 2021 and 2020, respectively. Total stock compensation expense associated with employee awards for the three months ended January 31, 2021 and 2020 was approximately $0 and $56,000, respectively.   Stock Options   A summary of changes in the stock option plan for the three months ended January 31, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding as of October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1,011,768</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">33.43</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">4</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(14,391</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">21.49</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,047,377</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">32.02</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.89</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">143</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Vested and exercisable at January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">313,268</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">103.55</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">18</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price Range</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">0.30-$10.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">793,412</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9.20</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">83,201</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">10.01-$100.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">91,727</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.93</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">67,829</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.83</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">31.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">100.01-$200.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">200.01-$277.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td></tr> </table>   During the three months end January 31, 2021, the Company granted options to purchase 50,000 shares of its common stock to an employee. The stock options have a ten-year term, vest over three years from the date of grant, and have an exercise price of $0.39.   Total compensation cost related to the Company’s outstanding stock options, recognized in the condensed statements of operations for the three months ended January 31, 2021 and 2020 was approximately $0.2 million.   As of January 31, 2021, there was approximately $0.4 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.54 years.   As of January 31, 2021, the aggregate intrinsic value of vested and exercisable options was $143 thousand and the aggregate intrinsic value of non-vested options was approximately $18 thousand.   In determining the fair value of the stock options granted during the three months ended January 31, 2021, the Company used the following inputs in its Black Scholes Merton model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">6 years </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 77%">Expected Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">103.27</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Dividends</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk Free Interest Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.53</td> <td>%</td></tr> </table>   Employee Stock Purchase Plan   During the three months ended January 31, 2021 and 2020, the Company issued 0 and 5,555 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

8. COLLABORATION AND LICENSING AGREEMENTS   OS Therapies LLC   On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.   In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement. The Company therefore transferred and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

9. COMMITMENTS AND CONTINGENCIES   Legal Proceedings   The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

10. LEASES   Operating Leases   The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the condensed balance sheet.   The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability.</td></tr> </table>   Supplemental balance sheet information related to leases as of January 31, 2021 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating leases: </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; padding-bottom: 1.5pt">Operating lease right-of-use assets</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">4,644</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating lease liability</td> <td> </td> <td>$</td> <td style="text-align: right">992</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating lease liability, net of current portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,795</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Total operating lease liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,787</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Supplemental lease expense related to leases was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 22%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 27%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%; text-align: right">290</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%; text-align: right">290</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">437</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">141</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">727</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">516</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Other information related to leases where the Company is the lessee is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Weighted-average remaining lease term</td> <td> </td> <td> </td> <td style="text-align: right">4.8 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; text-align: justify">Weighted-average discount rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">6.5</td> <td style="width: 1%">%</td></tr> </table>   Supplemental cash flow information related to operating leases was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">324</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">300</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Future minimum lease payments under non-cancellable leases as of January 31, 2021 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Fiscal Year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,369</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">1,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">1,419</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">1,444</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">993</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">6,740</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: Imputed interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(953</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,787</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Under ASC 842, future minimum payments under the Company’s operating lease were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Fiscal Year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">993</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">1,369</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">1,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">1,419</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">1,444</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">120</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,740</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Under ASC 842, rent expense for each of the three months ended January 31, 2021 and 2020 was approximately $0.3 million.

11. STOCKHOLDERS’ EQUITY   Public Offerings   In November 2020, the Company closed on a public offering of 30,666,665 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $9.2 million, which gives effect to the exercise of the underwriter’s option in full. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 15,333,332 shares of common stock. The warrants have an exercise price per share of $0.35, are exercisable immediately and will expire five years from the date of issuance. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million.   During the three months ended January 31, 2020, warrant holders from the Company’s November 2020 offering exercised 7,390,000 warrants in exchange for 7,390,000 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of about $2.6 million which were payable upon exercise.   A summary of the changes in stockholders’ equity for the three months ended January 31, 2021 and 2020 is presented below (in thousands, except share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Balance at November 1, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">     -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">       -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">50,201,671</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">423,750</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">(384,269</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">39,531</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,957</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,618</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,628</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,416</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,555</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at January 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,236,599</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">60</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">433,614</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(392,126</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">41,548</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Balance at November 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">     -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">       -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">78,074,023</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">440,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">(410,738</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">30,180</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,666,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,519</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,550</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,390,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,579</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,586</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at January 31, 2021</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">116,130,688</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">452,174</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(414,715</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">37,575</td> <td> </td></tr> </table>

12. FAIR VALUE   The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:   ● Level 1 — Quoted prices in active markets for identical assets or liabilities.   ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.   ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.   The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2021 and October 31, 2020 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">44</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">27</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Ending Balance</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">44</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

13. Subsequent Events   In February 2021, warrant holders exercised about 3.3 million warrants from the Company’s November 2020’s offering. The Company received aggregate proceeds of about $1.2 million from these exercises.

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">17</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Change in fair value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">27</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Ending Balance</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">44</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2021 and October 31, 2020 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">44</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Common stock warrant liability, warrants exercisable at $0.372 through September 2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">17</td> <td style="width: 1%"> </td></tr> </table>

A summary of the changes in stockholders’ equity for the three months ended January 31, 2021 and 2020 is presented below (in thousands, except share data):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Balance at November 1, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">     -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">       -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">50,201,671</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">423,750</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">(384,269</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">39,531</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,957</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">242</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,618</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,628</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,416</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Issuance of shares to employees under ESPP Plan</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,555</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,857</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at January 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">60,236,599</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">60</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">433,614</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(392,126</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">41,548</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Preferred Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional Paid-In</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Shareholders’</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Equity</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Balance at November 1, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">     -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">       -</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right">78,074,023</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">78</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">440,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">(410,738</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 5%; text-align: right">30,180</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Advaxis public offerings, net of offering costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">30,666,665</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,519</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,550</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7,390,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,579</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,586</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Net Loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,977</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance at January 31, 2021</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">116,130,688</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">116</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">452,174</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(414,715</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">37,575</td> <td> </td></tr> </table>

Under ASC 842, future minimum payments under the Company’s operating lease were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Fiscal Year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">993</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">1,369</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">1,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">1,419</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">1,444</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">120</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,740</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Future minimum lease payments under non-cancellable leases as of January 31, 2021 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Fiscal Year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,369</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">1,395</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">1,419</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">1,444</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">120</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">993</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">6,740</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: Imputed interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(953</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,787</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Supplemental cash flow information related to operating leases was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; padding-bottom: 1.5pt; text-align: justify">Cash paid for operating lease liabilities</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">324</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 16%; text-align: right">300</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> </table>

Other information related to leases where the Company is the lessee is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Weighted-average remaining lease term</td> <td> </td> <td> </td> <td style="text-align: right">4.8 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; text-align: justify">Weighted-average discount rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">6.5</td> <td style="width: 1%">%</td></tr> </table>

Supplemental lease expense related to leases was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Lease Cost (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Statements of Operations Classification</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended January 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 22%; text-align: justify">Operating lease cost</td> <td style="width: 1%"> </td> <td style="width: 27%; text-align: center">General and administrative</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%; text-align: right">290</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 22%; text-align: right">290</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Short-term lease cost</td> <td> </td> <td style="text-align: center">General and administrative</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">Variable lease cost</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">437</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">141</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify">Total lease expense</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">727</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">516</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

Supplemental balance sheet information related to leases as of January 31, 2021 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating leases: </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; padding-bottom: 1.5pt">Operating lease right-of-use assets</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%">$</td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">4,644</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating lease liability</td> <td> </td> <td>$</td> <td style="text-align: right">992</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating lease liability, net of current portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,795</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Total operating lease liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,787</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

In determining the fair value of the stock options granted during the three months ended January 31, 2021, the Company used the following inputs in its Black Scholes Merton model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">6 years </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 77%">Expected Volatility</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">103.27</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Dividends</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk Free Interest Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.53</td> <td>%</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">Exercise</td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Price Range</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Contractual</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">0.30-$10.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">793,412</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9.20</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">83,201</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">10.01-$100.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">91,727</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.93</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">29.17</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">67,829</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.83</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">31.01</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">100.01-$200.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">92,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.51</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">166.04</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">200.01-$277.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">69,391</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.33</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">210.79</td> <td> </td></tr> </table>

A summary of changes in the stock option plan for the three months ended January 31, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value (in thousands)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Outstanding as of October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1,011,768</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">33.43</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">4</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled or expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(14,391</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">21.49</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding as of January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,047,377</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">32.02</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.89</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">143</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Vested and exercisable at January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">313,268</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">103.55</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">18</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2021 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of RSUs</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Grant Date Fair Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Balance at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">5,556</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">24.32</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cancelled</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance at January 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,556</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">24.32</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended January 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Research and development</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">57</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">91</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">179</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">151</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">236</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

In measuring the warrant liability at January 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Exercise Price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.30</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.37</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.73</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.34</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Term</td> <td> </td> <td> </td> <td style="text-align: right">3.61 years</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.87 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility %</td> <td> </td> <td> </td> <td style="text-align: right">114</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk Free Rate</td> <td> </td> <td> </td> <td style="text-align: right">0.20</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.29</td> <td>%</td></tr> </table>

summary of warrant activity for the quarter ended January 31, 2021 is as follows (in thousands, except share and per share data):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life In Years</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Outstanding and exercisable warrants at October 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">398,226</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.08</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3.76</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">110,640</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">15,333,332</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.82</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(7,390,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.35</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding and exercisable warrants at January 31, 2021</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,341,558</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.45</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.76</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,048,937</td> <td> </td></tr> </table>

Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares Underlying Warrants</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">281.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: right">25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 28%">N/A</td> <td style="width: 1%"> </td> <td style="width: 23%">Other warrants</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,863</td> <td> </td> <td> </td> <td>July 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">2.80</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,338</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">0.35</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,943,332</td> <td> </td> <td> </td> <td>November 2025</td> <td> </td> <td>November 2020 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">Grand Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,341,558</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   As of October 31, 2020, there were outstanding warrants to purchase 398,226 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares Underlying Warrants</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration Date</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Type of Financing</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: right">327,338</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 28%">July 2024</td> <td style="width: 1%"> </td> <td style="width: 23%">July 2019 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right">281.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25</td> <td> </td> <td> </td> <td>N/A</td> <td> </td> <td>Other Warrants</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right">0.372</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,863</td> <td> </td> <td> </td> <td>September 2024</td> <td> </td> <td>September 2018 Public Offering</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right">Grand Total</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">398,226</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Salaries and other compensation</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">496</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">737</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Vendors</td> <td> </td> <td> </td> <td style="text-align: right">1,414</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">671</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Professional fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">232</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">329</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total accrued expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,142</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,737</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fiscal year ending October 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">2021 (Remaining)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">205</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2022</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2024</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">273</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,107</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,404</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Patents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,689</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">4,479</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Licenses</td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">777</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Software</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">117</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total intangibles</td> <td> </td> <td> </td> <td style="text-align: right">5,583</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,373</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,179</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,112</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,404</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and equipment, net consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">January 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">October 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Leasehold improvements</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">2,335</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Laboratory equipment</td> <td> </td> <td> </td> <td style="text-align: right">1,131</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,218</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Furniture and fixtures</td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">744</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer equipment</td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">409</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Construction in progress</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total property and equipment</td> <td> </td> <td> </td> <td style="text-align: right">4,638</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,725</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Accumulated depreciation and amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,449</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,332</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net property and equipment</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,189</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,393</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of January 31, 2021 and 2020. As of January 31, 2021 and 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of January 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">8,014,220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,405,726</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,047,377</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">553,446</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,556</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,644</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,067,153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,970,816</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Recent Accounting Standards   Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Net Income (Loss) per Share   Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of January 31, 2021 and 2020. As of January 31, 2021 and 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of January 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">8,014,220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,405,726</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,047,377</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">553,446</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,556</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,644</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,067,153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,970,816</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Basis of Presentation/Estimates   The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of January 31, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.   Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.   These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-KA filed on February 26, 2021.

P10Y

793412

91727

92847

69391

83201

67829

92847

69391

P9Y2M12D

P6Y11M4D

P2Y6M3D

P1Y3M29D

3.52

29.17

166.04

210.79

3.52

31.01

166.04

210.79

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION   Basis of Presentation/Estimates   The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed balance sheet as of January 31, 2021 has been derived from the Company’s October 31, 2020 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.   Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.   These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2020 and notes thereto contained in the Company’s 2020 Annual Report on Form 10-K, as filed with the SEC on January 22, 2021, and as amended by Amendment No. 1 thereto on Form 10-KA filed on February 26, 2021.   Net Income (Loss) per Share   Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of January 31, 2021 and 2020. As of January 31, 2021 and 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">As of January 31,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">8,014,220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">5,405,726</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">1,047,377</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">553,446</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Restricted stock units</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,556</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,644</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,067,153</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,970,816</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Recent Accounting Standards   Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

119466620

EX-101.SCH 7 adxs-20200131.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock Purchase Warrants and Warrant Liability link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Share Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Collaboration and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Nature of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Share Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Share Based Compensation - Summary of Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Share Based Compensation - Summary of RSU Activity and Related Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Share Based Compensation - Summary of Changes in Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Collaboration and Licensing Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Leases - Schedule of Lease Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Stockholders' Equity - Summary of Stockholders Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 adxs-20200131_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 adxs-20200131_def.xml XBRL DEFINITION FILE EX-101.LAB 10 adxs-20200131_lab.xml XBRL LABEL FILE Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Components [Axis] Equity Warrants [Member] Warrant Liability [Member] Derivative Instrument [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Measurement Input Type [Axis] Expected Term [Member] Volatility [Member] Risk Free Rate [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Sale of Stock [Axis] Public Offering [Member] Private Placement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Development, License and Supply Agreement [Member] Scenario [Axis] OS Therapies [Member] Legal Entity [Axis] OS Therapies LLC [Member] Milestone set forth in the Licence Agreement [Member] Income Statement Location [Axis] General and Administrative [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Warrants [Member] Antidilutive Securities [Axis] Stock Options [Member] Restricted Stock Units [Member] Exercise Price Range Four [Member] Employee Stock Awards [Member] Plan Name [Axis] 2018 Employee Stock Purchase Plan [Member] Research and Development [Member] Subsequent Event Type [Axis] Subsequent Event [Member] November 2020 Offering [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Deferred expenses Prepaid expenses and other current assets Total current assets Property and equipment (net of accumulated depreciation) Intangible assets (net of accumulated amortization) Operating right-of-use asset (net of accumulated amortization) Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Common stock warrant liability Current portion of operating lease liability Deferred revenue Total current liabilities Operating lease liability, net of current portion Total liabilities Commitments and contingencies - Note 9 Stockholders' equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2021 and October 31, 2020; Liquidation preference of $0 at January 31, 2021 and October 31, 2020 Common stock - $0.001 par value; 170,000,000 shares authorized, 116,130,688 and 78,074,023 shares issued and outstanding at January 31, 2021 and October 31, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference value Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development expenses General and administrative expenses Total operating expenses Loss from operations Other income (expense): Interest income, net Net changes in fair value of derivative liabilities Other income Net loss before benefit for income taxes Income tax expense Net loss Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock compensation Loss on change in value of warrants Loss on disposal of property and equipment Abandonment of intangible assets Depreciation expense Amortization expense of intangible assets Amortization of right-of-use asset Change in operating assets and liabilities: Prepaid expenses and other current assets Other assets Accounts payable and accrued expenses Deferred revenue Operating lease liabilities Net cash used in operating activities INVESTING ACTIVITIES Cost of intangible assets Net cash used in investing activities FINANCING ACTIVITIES Net proceeds of issuance of common stock Warrant exercise Proceeds from employee stock purchase plan Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for taxes SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES Warrant liability reclassified into equity Amounts accrued for offering costs Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations Accounting Policies [Abstract] Summary of Significant Accounting Policies and Basis of Presentation Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Common Stock Purchase Warrants And Warrant Liability Common Stock Purchase Warrants and Warrant Liability Share-based Payment Arrangement [Abstract] Share Based Compensation Business Combinations [Abstract] Collaboration and Licensing Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases [Abstract] Leases Equity [Abstract] Stockholders' Equity Fair Value Disclosures [Abstract] Fair Value Subsequent Events [Abstract] Subsequent Events Basis of Presentation/Estimates Net Income (Loss) Per Share Recent Accounting Standards Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share Schedule of Property and Equipment Summary of Intangible Assets Schedule of Carrying Value of Intangible Assets Summary of Accrued Expenses Schedule of Outstanding Warrants Schedule of Warrants Activity Schedule of Assumptions Used in Warrant Liability Summary of Share Based Compensation Expense Summary of RSU Activity and Related Information EX-101.PRE 11 adxs-20200131_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jan. 31, 2021	Mar. 08, 2021
Cover [Abstract]
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jan. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		119,466,620
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Current Assets:
Cash and cash equivalents	$ 33,318	$ 25,178
Deferred expenses	1,602	1,808
Prepaid expenses and other current assets	608	865
Total current assets	35,528	27,851
Property and equipment (net of accumulated depreciation)	2,189	2,393
Intangible assets (net of accumulated amortization)	3,404	3,261
Operating right-of-use asset (net of accumulated amortization)	4,644	4,839
Other assets	182	182
Total assets	45,947	38,526
Current liabilities:
Accounts payable	399	410
Accrued expenses	2,142	1,737
Common stock warrant liability	44	17
Current portion of operating lease liability	992	962
Deferred revenue		165
Total current liabilities	3,577	3,291
Operating lease liability, net of current portion	4,795	5,055
Total liabilities	8,372	8,346
Commitments and contingencies - Note 9
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at January 31, 2021 and October 31, 2020; Liquidation preference of $0 at January 31, 2021 and October 31, 2020
Common stock - $0.001 par value; 170,000,000 shares authorized, 116,130,688 and 78,074,023 shares issued and outstanding at January 31, 2021 and October 31, 2020, respectively	116	78
Additional paid-in capital	452,174	440,840
Accumulated deficit	(414,715)	(410,738)
Total stockholders' equity	37,575	30,180
Total liabilities and stockholders' equity	$ 45,947	$ 38,526

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	116,130,688	78,074,023
Common stock, shares outstanding	116,130,688	78,074,023

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Income Statement [Abstract]
Revenue	$ 1,615	$ 3
Operating expenses:
Research and development expenses	2,570	4,859
General and administrative expenses	3,008	3,030
Total operating expenses	5,578	7,889
Loss from operations	(3,963)	(7,886)
Other income (expense):
Interest income, net	1	66
Net changes in fair value of derivative liabilities	(27)	(37)
Other income	12
Net loss before benefit for income taxes	(3,977)	(7,857)
Income tax expense
Net loss	$ (3,977)	$ (7,857)
Net loss per common share, basic and diluted	$ (0.05)	$ (0.15)
Weighted average number of common shares outstanding, basic and diluted	83,943,982	51,747,246

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
OPERATING ACTIVITIES
Net loss	$ (3,977)	$ (7,857)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	236	242
Loss on change in value of warrants	27	37
Loss on disposal of property and equipment	12
Abandonment of intangible assets		232
Depreciation expense	192	229
Amortization expense of intangible assets	67	91
Amortization of right-of-use asset	195	181
Change in operating assets and liabilities:
Prepaid expenses and other current assets	463	789
Other assets		1
Accounts payable and accrued expenses	394	(1,462)
Deferred revenue	(165)
Operating lease liabilities	(230)	(191)
Net cash used in operating activities	(2,786)	(7,708)
INVESTING ACTIVITIES
Cost of intangible assets	(210)	(238)
Net cash used in investing activities	(210)	(238)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	8,550	9,737
Warrant exercise	2,586
Proceeds from employee stock purchase plan		2
Net cash provided by financing activities	11,136	9,739
Net increase in cash and cash equivalents	8,140	1,793
Cash and cash equivalents at beginning of period	25,178	32,363
Cash and cash equivalents at end of period	33,318	34,156
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Warrant liability reclassified into equity		2
Amounts accrued for offering costs		$ 109

XML 17 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations

3 Months Ended

Jan. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS

	●	Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
	●	Attacking the tumor by generating a strong, cancer-specific T cell response; and
	●	Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

Liquidity and Capital Resources

Liquidity and Management’s Plans

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation

3 Months Ended

Jan. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation/Estimates

Net Income (Loss) per Share

	As of January 31,
	2021		2020
Warrants		8,014,220		5,405,726
Stock options		1,047,377		553,446
Restricted stock units		5,556		11,644
Total		9,067,153		5,970,816

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

3 Months Ended

Jan. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

3. PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Leasehold improvements	$	2,335		$	2,335
Laboratory equipment		1,131			1,218
Furniture and fixtures		744			744
Computer equipment		409			409
Construction in progress		19			19
Total property and equipment		4,638			4,725
Accumulated depreciation and amortization		(2,449	)		(2,332	)
Net property and equipment	$	2,189		$	2,393

Depreciation expense for the three months ended January 31, 2021 and 2020 was $0.2 million.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Jan. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Patents	$	4,689		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,583			5,373
Accumulated amortization		(2,179	)		(2,112	)
Intangible assets	$	3,404		$	3,261

As of January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	205
2022		273
2023		273
2024		273
2025		273
Thereafter		2,107
Total	$	3,404

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Jan. 31, 2021

Payables and Accruals [Abstract]

Accrued Expenses

5. ACCRUED EXPENSES:

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	January 31, 2021		October 31, 2020

Salaries and other compensation	$	496	$	737
Vendors		1,414		671
Professional fees		232		329
Total accrued expenses	$	2,142	$	1,737

XML 22 R11.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability

3 Months Ended

Jan. 31, 2021

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,863	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		7,943,332	November 2025	November 2020 Public Offering
	Grand Total		8,341,558

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

A summary of warrant activity for the quarter ended January 31, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		15,333,332			0.35		4.82
Exercised		(7,390,000	)		0.35
Outstanding and exercisable warrants at January 31, 2021		8,341,558		$	0.45		4.76	$	3,048,937

Warrant Liability

In measuring the warrant liability at January 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	January 31, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.73		$	0.34
Expected Term		3.61 years			3.87 years
Volatility %		114	%		106	%
Risk Free Rate		0.20	%		0.29	%

XML 23 R12.htm IDEA: XBRL DOCUMENT

Share Based Compensation

3 Months Ended

Jan. 31, 2021

Share-based Payment Arrangement [Abstract]

Share Based Compensation

7. SHARE BASED COMPENSATION

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended January 31,
	2021		2020
Research and development	$	57	$	91
General and administrative		179		151
Total	$	236	$	242

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2021 is as follows:

	Number of RSUs		Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556	$	24.32
Vested		-
Cancelled		-
Balance at January 31, 2021		5,556	$	24.32

As of January 31, 2021, the aggregate intrinsic value of non-vested RSU’s was approximately $4,100.

Employee Stock Awards

Stock Options

A summary of changes in the stock option plan for the three months ended January 31, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Cancelled or expired		(14,391	)		21.49
Outstanding as of January 31, 2021		1,047,377		$	32.02		7.89	$	143
Vested and exercisable at January 31, 2021		313,268		$	103.55		4.72	$	18

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	0.30-$10.00		793,412		9.20	$	3.52		83,201		8.30	$	3.52
$	10.01-$100.00		91,727		6.93	$	29.17		67,829		6.83	$	31.01
$	100.01-$200.00		92,847		2.51	$	166.04		92,847		2.51	$	166.04
$	200.01-$277.50		69,391		1.33	$	210.79		69,391		1.33	$	210.79

As of January 31, 2021, the aggregate intrinsic value of vested and exercisable options was $143 thousand and the aggregate intrinsic value of non-vested options was approximately $18 thousand.

In determining the fair value of the stock options granted during the three months ended January 31, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Three Months Ended January 31, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

Employee Stock Purchase Plan

During the three months ended January 31, 2021 and 2020, the Company issued 0 and 5,555 shares, respectively, that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

XML 24 R13.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Agreements

3 Months Ended

Jan. 31, 2021

Business Combinations [Abstract]

Collaboration and Licensing Agreements

8. COLLABORATION AND LICENSING AGREEMENTS

OS Therapies LLC

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Jan. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

XML 26 R15.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Jan. 31, 2021

Leases [Abstract]

Leases

10. LEASES

Operating Leases

The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities:

	●	As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease.

	●	Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component.

	●	Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise.

	●	Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability.

Supplemental balance sheet information related to leases as of January 31, 2021 is as follows (in thousands):

Operating leases:
Operating lease right-of-use assets	$	4,644

Operating lease liability	$	992
Operating lease liability, net of current portion		4,795
Total operating lease liabilities	$	5,787

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended January 31, 2021		For the Three Months Ended January 31, 2020
Operating lease cost	General and administrative		290		290
Short-term lease cost	General and administrative		-		85
Variable lease cost	General and administrative	$	437		141
Total lease expense		$	727		516

Other information related to leases where the Company is the lessee is as follows:

	For the Three Months Ended January 31, 2021
Weighted-average remaining lease term		4.8 years
Weighted-average discount rate		6.5	%

Supplemental cash flow information related to operating leases was as follows:

	For the Three Months Ended January 31, 2021		For the Three Months Ended January 31, 2020
Cash paid for operating lease liabilities	$	324		300

Future minimum lease payments under non-cancellable leases as of January 31, 2021 is as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	1,369
2022		1,395
2023		1,419
2024		1,444
2025		120
Thereafter		993
Total minimum lease payments		6,740
Less: Imputed interest		(953	)
Total	$	5,787

Under ASC 842, future minimum payments under the Company’s operating lease were as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	993
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total	$	6,740

Under ASC 842, rent expense for each of the three months ended January 31, 2021 and 2020 was approximately $0.3 million.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Jan. 31, 2021

Equity [Abstract]

Stockholders' Equity

11. STOCKHOLDERS’ EQUITY

Public Offerings

A summary of the changes in stockholders’ equity for the three months ended January 31, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575

XML 28 R17.htm IDEA: XBRL DOCUMENT

Fair Value

3 Months Ended

Jan. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value

12. FAIR VALUE

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2021 and October 31, 2020 (in thousands):

January 31, 2021	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	44	$	44

October 31, 2020	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	17	$	17

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Three Months Ended January 31, 2021
Beginning balance	$	17
Warrant exercises		-
Change in fair value		27
Ending Balance	$	44

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Jan. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

3 Months Ended

Jan. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation/Estimates

Basis of Presentation/Estimates

Net Income (Loss) Per Share

Net Income (Loss) per Share

	As of January 31,
	2021		2020
Warrants		8,014,220		5,405,726
Stock options		1,047,377		553,446
Restricted stock units		5,556		11,644
Total		9,067,153		5,970,816

Recent Accounting Standards

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

3 Months Ended

Jan. 31, 2021

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share

The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share as of January 31, 2021 and 2020. As of January 31, 2021 and 2020, 0 and 343,838 warrants, respectively, are included in the basic earnings per share computation because the exercise price was $0.

	As of January 31,
	2021		2020
Warrants		8,014,220		5,405,726
Stock options		1,047,377		553,446
Restricted stock units		5,556		11,644
Total		9,067,153		5,970,816

XML 32 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

3 Months Ended

Jan. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Leasehold improvements	$	2,335		$	2,335
Laboratory equipment		1,131			1,218
Furniture and fixtures		744			744
Computer equipment		409			409
Construction in progress		19			19
Total property and equipment		4,638			4,725
Accumulated depreciation and amortization		(2,449	)		(2,332	)
Net property and equipment	$	2,189		$	2,393

XML 33 R22.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Jan. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets, net consisted of the following (in thousands):

	January 31, 2021			October 31, 2020

Patents	$	4,689		$	4,479
Licenses		777			777
Software		117			117
Total intangibles		5,583			5,373
Accumulated amortization		(2,179	)		(2,112	)
Intangible assets	$	3,404		$	3,261

Schedule of Carrying Value of Intangible Assets

As of January 31, 2021, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

	Fiscal year ending October 31,

2021 (Remaining)	$	205
2022		273
2023		273
2024		273
2025		273
Thereafter		2,107
Total	$	3,404

XML 34 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Jan. 31, 2021

Payables and Accruals [Abstract]

Summary of Accrued Expenses

The following table summarizes accrued expenses included in the condensed balance sheets (in thousands):

	January 31, 2021		October 31, 2020

Salaries and other compensation	$	496	$	737
Vendors		1,414		671
Professional fees		232		329
Total accrued expenses	$	2,142	$	1,737

XML 35 R24.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability (Tables)

3 Months Ended

Jan. 31, 2021

Common Stock Purchase Warrants And Warrant Liability

Schedule of Outstanding Warrants

Information on the outstanding warrants is as follows:

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	281.25		25	N/A	Other warrants
$	0.30		70,863	July 2024	September 2018 Public Offering
$	2.80		327,338	September 2024	July 2019 Public Offering
$	0.35		7,943,332	November 2025	November 2020 Public Offering
	Grand Total		8,341,558

Exercise Price		Number of Shares Underlying Warrants		Expiration Date	Type of Financing
$	-		327,338	July 2024	July 2019 Public Offering
$	281.25		25	N/A	Other Warrants
$	0.372		70,863	September 2024	September 2018 Public Offering
	Grand Total		398,226

Schedule of Warrants Activity

summary of warrant activity for the quarter ended January 31, 2021 is as follows (in thousands, except share and per share data):

	Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and exercisable warrants at October 31, 2020		398,226		$	0.08		3.76	$	110,640
Issued		15,333,332			0.35		4.82
Exercised		(7,390,000	)		0.35
Outstanding and exercisable warrants at January 31, 2021		8,341,558		$	0.45		4.76	$	3,048,937

Schedule of Assumptions Used in Warrant Liability

In measuring the warrant liability at January 31, 2021 and October 31, 2020, the Company used the following inputs in its Monte Carlo simulation model:

	January 31, 2021			October 31, 2020
Exercise Price	$	0.30		$	0.37
Stock Price	$	0.73		$	0.34
Expected Term		3.61 years			3.87 years
Volatility %		114	%		106	%
Risk Free Rate		0.20	%		0.29	%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Share Based Compensation (Tables)

3 Months Ended

Jan. 31, 2021

Share-based Payment Arrangement [Abstract]

Summary of Share Based Compensation Expense

The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands):

	Three Months Ended January 31,
	2021		2020
Research and development	$	57	$	91
General and administrative		179		151
Total	$	236	$	242

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the three months ended January 31, 2021 is as follows:

	Number of RSUs		Weighted-Average Grant Date Fair Value

Balance at October 31, 2020		5,556	$	24.32
Vested		-
Cancelled		-
Balance at January 31, 2021		5,556	$	24.32

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the three months ended January 31, 2021 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value (in thousands)
Outstanding as of October 31, 2020		1,011,768		$	33.43		8.04	$	4
Granted		50,000			0.39
Cancelled or expired		(14,391	)		21.49
Outstanding as of January 31, 2021		1,047,377		$	32.02		7.89	$	143
Vested and exercisable at January 31, 2021		313,268		$	103.55		4.72	$	18

Summary of Outstanding and Exercisable Options

Options Outstanding								Options Exercisable
				Weighted		Weighted				Weighted		Weighted
				Average		Average				Average		Average
Exercise		Number		Remaining		Exercise		Number		Remaining		Exercise
Price Range		Outstanding		Contractual		Price		Exercisable		Contractual		Price
$	0.30-$10.00		793,412		9.20	$	3.52		83,201		8.30	$	3.52
$	10.01-$100.00		91,727		6.93	$	29.17		67,829		6.83	$	31.01
$	100.01-$200.00		92,847		2.51	$	166.04		92,847		2.51	$	166.04
$	200.01-$277.50		69,391		1.33	$	210.79		69,391		1.33	$	210.79

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the three months ended January 31, 2021, the Company used the following inputs in its Black Scholes Merton model:

	Three Months Ended January 31, 2021

Expected Term		6 years
Expected Volatility		103.27	%
Expected Dividends		0	%
Risk Free Interest Rate		0.53	%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Jan. 31, 2021

Leases [Abstract]

Schedule of Supplemental Balance Sheet Related to Leases

Supplemental balance sheet information related to leases as of January 31, 2021 is as follows (in thousands):

Operating leases:
Operating lease right-of-use assets	$	4,644

Operating lease liability	$	992
Operating lease liability, net of current portion		4,795
Total operating lease liabilities	$	5,787

Schedule of Lease Expenses

Supplemental lease expense related to leases was as follows (in thousands):

Lease Cost (in thousands)	Statements of Operations Classification	For the Three Months Ended January 31, 2021		For the Three Months Ended January 31, 2020
Operating lease cost	General and administrative		290		290
Short-term lease cost	General and administrative		-		85
Variable lease cost	General and administrative	$	437		141
Total lease expense		$	727		516

Schedule of Other Information Related to Leases

Other information related to leases where the Company is the lessee is as follows:

	For the Three Months Ended January 31, 2021
Weighted-average remaining lease term		4.8 years
Weighted-average discount rate		6.5	%

Schedule of Cash Flow Information Related to Leases

Supplemental cash flow information related to operating leases was as follows:

		For the Three Months Ended January 31, 2021				For the Three Months Ended January 31, 2020
Cash paid for operating lease liabilities		$	324				300

Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases

Future minimum lease payments under non-cancellable leases as of January 31, 2021 is as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	1,369
2022		1,395
2023		1,419
2024		1,444
2025		120
Thereafter		993
Total minimum lease payments		6,740
Less: Imputed interest		(953	)
Total	$	5,787

Schedule of Future Minimum Payments Under Operating Lease

Under ASC 842, future minimum payments under the Company’s operating lease were as follows (in thousands):

Fiscal Year ending October 31,
2021 (Remaining)	$	993
2022		1,369
2023		1,395
2024		1,419
2025		1,444
Thereafter		120
Total	$	6,740

XML 38 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Jan. 31, 2021

Equity [Abstract]

Summary of Stockholders Equity

A summary of the changes in stockholders’ equity for the three months ended January 31, 2021 and 2020 is presented below (in thousands, except share data):

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2019		-	$	-		50,201,671	$	50	$	423,750	$	(384,269	)	$	39,531
Stock-based compensation		-		-		2,957		-		242		-			242
Advaxis public offerings, net of offering costs		-		-		10,000,000		10		9,618		-			9,628
Warrant exercises		-		-		26,416		-		2		-			2
Issuance of shares to employees under ESPP Plan		-		-		5,555		-		2		-			2
Net Loss		-		-		-		-		-		(7,857	)		(7,857	)
Balance at January 31, 2020		-	$	-		60,236,599	$	60	$	433,614	$	(392,126	)	$	41,548

	Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at November 1, 2020		-	$	-		78,074,023	$	78	$	440,840	$	(410,738	)	$	30,180
Stock-based compensation		-		-		-		-		236		-			236
Advaxis public offerings, net of offering costs		-		-		30,666,665		31		8,519		-			8,550
Warrant exercises		-		-		7,390,000		7		2,579		-			2,586
Net Loss		-		-		-		-		-		(3,977	)		(3,977	)
Balance at January 31, 2021		-	$	-		116,130,688	$	116	$	452,174	$	(414,715	)	$	37,575

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value (Tables)

3 Months Ended

Jan. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2021 and October 31, 2020 (in thousands):

January 31, 2021	Level 1		Level 2		Level 3		Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024		-		-	$	44	$	44

October 31, 2020		Level 1				Level 2				Level 3				Total
Common stock warrant liability, warrants exercisable at $0.372 through September 2024			-				-			$	17			$	17

Schedule of Changes in Fair Value of Warrant Liabilities

The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities (in thousands):

	For the Three Months Ended January 31, 2021
Beginning balance	$	17
Warrant exercises		-
Change in fair value		27
Ending Balance	$	44

XML 40 R29.htm IDEA: XBRL DOCUMENT

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 33,318		$ 25,178
Proceeds from warrant exercise	$ 2,586

XML 41 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - $ / shares	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Number of securities included in computation of basic earnings per share	9,067,153	5,970,816
Exercise price	$ 0	$ 0
Warrants [Member]
Number of securities included in computation of basic earnings per share	0	343,838

XML 42 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Total	9,067,153	5,970,816
Warrants [Member]
Total	8,014,220	5,405,726
Stock Options [Member]
Total	1,047,377	553,446
Restricted Stock Units [Member]
Total	5,556	11,644

XML 43 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 192	$ 229

XML 44 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,335
Laboratory equipment	1,131	1,218
Furniture and fixtures	744	744
Computer equipment	409	409
Construction in progress	19	19
Total property and equipment	4,638	4,725
Accumulated depreciation and amortization	(2,449)	(2,332)
Net property and equipment	$ 2,189	$ 2,393

XML 45 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Expiration of patents description	The expiration dates of the existing patents range from 2021 to 2040.
Book value patent applications, net		$ 232
Intangible asset amortization expense	$ 67	$ 91

XML 46 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,689	$ 4,479
Licenses	777	777
Software	117	117
Total intangibles	5,583	5,373
Accumulated amortization	(2,179)	(2,112)
Intangible assets	$ 3,404	$ 3,261

XML 47 R36.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Jan. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021 (Remaining)	$ 205
2022	273
2023	273
2024	273
2025	273
Thereafter	2,107
Total	$ 3,404

XML 48 R37.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Salaries and other compensation	$ 496	$ 737
Vendors	1,414	671
Professional fees	232	329
Total accrued expenses	$ 2,142	$ 1,737

XML 49 R38.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Jan. 31, 2021	Oct. 31, 2020	Jan. 31, 2020
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	8,341,558	398,226	7,390,000
Warrant exercise price per share	$ 0.372	$ 0.372
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	8,270,695	327,363
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	70,863	70,863
Warrant exercise price per share	$ 0.30	$ 0.37
Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0	0
Minimum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	0.30
Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	281.25	$ 281.25
Maximum [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share	$ 22.50

XML 50 R39.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jan. 31, 2021	Oct. 31, 2020	Jan. 31, 2020
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	8,341,558	398,226	7,390,000
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25
Number of Shares Underlying Warrants	25	327,338
Expiration Date		Jul. 31, 2024
Type of Financing	Other warrants	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.30	$ 281.25
Number of Shares Underlying Warrants	70,863	25
Expiration Date	Jul. 31, 2024
Type of Financing	September 2018 Public Offering	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.80	$ 0.372
Number of Shares Underlying Warrants	327,338	70,863
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Type of Financing	July 2019 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.35
Number of Shares Underlying Warrants	7,943,332
Expiration Date	Nov. 30, 2025
Type of Financing	November 2020 Public Offering

XML 51 R40.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jan. 31, 2021 USD ($) $ / shares shares
Common Stock Purchase Warrants And Warrant Liability
Warrants, Outstanding and exercisable warrants, Beginning balance \| shares	398,226
Warrants, Issued \| shares	15,333,332
Warrants, Exercised \| shares	(7,390,000)
Warrants, Outstanding and exercisable warrants, Ending balance \| shares	8,341,558
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning \| $ / shares	$ 0.08
Weighted Average Exercise Price, Issued \| $ / shares	0.35
Weighted Average Exercise Price, Exercised \| $ / shares	0.35
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending \| $ / shares	$ 0.45
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	3 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Issued	4 years 9 months 25 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	4 years 9 months 3 days
Aggregate Intrinsic Value, Beginning \| $	$ 110,640
Aggregate Intrinsic Value, Ending \| $	$ 3,048,937

XML 52 R41.htm IDEA: XBRL DOCUMENT

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details)	Jan. 31, 2021 $ / shares	Oct. 31, 2020 $ / shares	Jan. 31, 2020 $ / shares
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Stock Price	0		$ 0
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.30	0.37
Stock Price	$ 0.73	$ 0.34
Warrant Liability [Member] \| Expected Term [Member]
Class of Warrant or Right [Line Items]
Expected Term	3 years 7 months 10 days	3 years 10 months 14 days
Warrant Liability [Member] \| Volatility [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	114	106
Warrant Liability [Member] \| Risk Free Rate [Member]
Class of Warrant or Right [Line Items]
Measurement input percentage	0.20	0.29

XML 53 R42.htm IDEA: XBRL DOCUMENT

Share Based Compensation (Details Narrative) - USD ($)	3 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Unrecognized compensation cost related to non-vested stock option awards	$ 400,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	1 year 6 months 14 days
Stock compensation expense	$ 236,000	$ 242,000
Stock granted options to purchase	50,000
Stock option term	P10Y
Stock option vesting period	3 years
Stock option exercise price	$ 0.39		$ 33.43
Compensation cost related to outstanding stock options	$ 200,000	$ 200,000
Aggregate intrinsic value of vested and exercisable options	143,000
Aggregate intrinsic value of non-vested options	18,000		$ 4,000
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	$ 30,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	2 months 19 days
Aggregate intrinsic value of non-vested RSU	$ 4,100
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	0	2,957
Stock compensation expense	$ 0	$ 56,000
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan	0	5,555

XML 54 R43.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Share-based compensation expense	$ 236	$ 242
Research and Development [Member]
Share-based compensation expense	57	91
General and Administrative [Member]
Share-based compensation expense	$ 179	$ 151

XML 55 R44.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Jan. 31, 2021 $ / shares shares
Number of RSUs, Unvested Beginning Balance	5,556
Number of RSUs, Vested
Number of RSUs, Cancelled
Number of RSUs, Unvested Ending Balance	5,556
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance \| $ / shares	$ 24.32
Weighted-Average Grant Date Fair Value, Unvested Ending Balance \| $ / shares	$ 24.32

XML 56 R45.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	3 Months Ended
	Jan. 31, 2021 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Shares, Outstanding, Beginning Balance \| shares	1,011,768
Shares, Granted \| shares	50,000
Shares, Cancelled or Expired \| shares	(14,391)
Shares, Outstanding, Ending Balance \| shares	1,047,377
Shares, Vested and Exercisable \| shares	313,268
Weighted Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 33.43
Weighted Average Exercise Price, Granted \| $ / shares	0.39
Weighted Average Exercise Price, Cancelled or Expired \| $ / shares	21.49
Weighted Average Exercise Price, Outstanding, Ending \| $ / shares	0.39
Weighted Average Exercise Price, Vested and Exercisable \| $ / shares	$ 103.55
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	8 years 15 days
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending balance	7 years 10 months 21 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 8 months 19 days
Aggregate Intrinsic Value, Beginning \| $	$ 4,000
Aggregate Intrinsic Value, Ending \| $	18,000
Aggregate Intrinsic Value, Vested and Exercisable \| $	$ 18,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details)	3 Months Ended
	Jan. 31, 2021 $ / shares shares
Exercise Price Range One [Member]
Exercise Price Range, lower limit	$ 0.30
Exercise Price Range, upper limit	$ 10.00
Number Outstanding, Options Outstanding \| shares	793,412
Weighted Average Remaining Contractual, Options Outstanding	9 years 2 months 12 days
Weighted Average Exercise Price, Options Outstanding	$ 3.52
Number Outstanding, Options Exercisable \| shares	83,201
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	8 years 3 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 3.52
Exercise Price Range Two [Member]
Exercise Price Range, lower limit	10.01
Exercise Price Range, upper limit	$ 100.00
Number Outstanding, Options Outstanding \| shares	91,727
Weighted Average Remaining Contractual, Options Outstanding	6 years 11 months 4 days
Weighted Average Exercise Price, Options Outstanding	$ 29.17
Number Outstanding, Options Exercisable \| shares	67,829
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	6 years 9 months 29 days
Weighted Average Exercise Price, Options Exercisable	$ 31.01
Exercise Price Range Three [Member]
Exercise Price Range, lower limit	100.01
Exercise Price Range, upper limit	$ 200.00
Number Outstanding, Options Outstanding \| shares	92,847
Weighted Average Remaining Contractual, Options Outstanding	2 years 6 months 3 days
Weighted Average Exercise Price, Options Outstanding	$ 166.04
Number Outstanding, Options Exercisable \| shares	92,847
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	2 years 6 months 3 days
Weighted Average Exercise Price, Options Exercisable	$ 166.04
Exercise Price Range Four [Member]
Exercise Price Range, lower limit	200.01
Exercise Price Range, upper limit	$ 277.50
Number Outstanding, Options Outstanding \| shares	69,391
Weighted Average Remaining Contractual, Options Outstanding	1 year 3 months 29 days
Weighted Average Exercise Price, Options Outstanding	$ 210.79
Number Outstanding, Options Exercisable \| shares	69,391
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable	1 year 3 months 29 days
Weighted Average Exercise Price, Options Exercisable	$ 210.79

XML 58 R47.htm IDEA: XBRL DOCUMENT

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	3 Months Ended
	Jan. 31, 2021
Share-based Payment Arrangement [Abstract]
Expected Term	6 years
Expected Volatility	103.27%
Expected Dividends	0.00%
Risk Free Interest Rate	0.53%

XML 59 R48.htm IDEA: XBRL DOCUMENT

Collaboration and Licensing Agreements (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Apr. 30, 2020	Jan. 31, 2021	Dec. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Revenue				$ 1,615,000	$ 3,000
Development, License and Supply Agreement [Member] \| OS Therapies [Member]
Revenue	$ 25,000
Funding milestone payment	$ 2,337,500
Milestone set forth in the Licence Agreement [Member] \| OS Therapies LLC [Member]
Milestone achievement, description		The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.	The Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement.

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 60 R49.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
Leases (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2021	Jan. 31, 2020
Leases [Abstract]
Operating lease expiration	Nov. 30, 2025
Security deposit	$ 182
Rent expense	$ 300	$ 300

XML 61 R50.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Operating lease right-of-use assets	$ 4,644	$ 4,839
Operating lease liability	992	962
Operating lease liability, net of current portion	4,795	$ 5,055
Total operating lease liabilities	$ 5,787

XML 62 R51.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Operating lease cost	$ 290	$ 290
Short-term lease cost		85
Variable lease cost	437	141
Total lease expense	$ 727	$ 516

XML 63 R52.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Other Information Related to Leases (Details)	Jan. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term	4 years 9 months 18 days
Weighted-average discount rate	6.50%

XML 64 R53.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Leases [Abstract]
Cash paid for operating lease liabilities	$ 324	$ 300

XML 65 R54.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) $ in Thousands	Jan. 31, 2021 USD ($)
Leases [Abstract]
2021 (Remaining)	$ 1,369
2022	1,395
2023	1,419
2024	1,444
2025	120
Thereafter	993
Total minimum lease payments	6,740
Less: Imputed interest	(953)
Total	$ 5,787

XML 66 R55.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) $ in Thousands	Jan. 31, 2021 USD ($)
Leases [Abstract]
2021 (Remaining)	$ 993
2022	1,369
2023	1,395
2024	1,419
2025	1,444
Thereafter	120
Total	$ 6,740

XML 67 R56.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2020	Jan. 31, 2020	Jan. 31, 2021	Oct. 31, 2020
Number of warrants to purchase common stock		7,390,000	8,341,558	398,226
Net proceeds from offering	$ 8,500	$ 2,600
Warrants exercise price			$ 0.372	$ 0.372
Public Offering [Member]
Number of common stock shares sold	30,666,665
Share price per share	$ 0.30
Proceeds from sale of common shares	$ 9,200
Private Placement [Member]
Number of warrants to purchase common stock	15,333,332
Warrants exercise price	$ 0.35

XML 68 R57.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Beginning balance	$ 30,180	$ 39,531
Stock-based compensation	236	242
Advaxis public offerings, net of offering costs	8,550	9,628
Warrant exercises	2,586	2
Issuance of shares to employees under ESPP Plan		2
Net Loss	(3,977)	(7,857)
Ending balance	37,575	41,548
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock-based compensation
Stock-based compensation, shares
Advaxis public offerings, net of offering costs
Advaxis public offerings, net of offering costs, shares
Warrant exercises
Warrant exercises, shares
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
Net Loss
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 78	$ 50
Beginning balance, shares	78,074,023	50,201,671
Stock-based compensation
Stock-based compensation, shares		2,957
Advaxis public offerings, net of offering costs	$ 31	$ 10
Advaxis public offerings, net of offering costs, shares	30,666,665	10,000,000
Warrant exercises	$ 7
Warrant exercises, shares	7,390,000	26,416
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares		5,555
Net Loss
Ending balance	$ 116	$ 60
Ending balance, shares	116,130,688	60,236,599
Additional Paid-In Capital [Member]
Beginning balance	$ 440,840	$ 423,750
Stock-based compensation	236	242
Advaxis public offerings, net of offering costs	8,519	9,618
Warrant exercises	2,579	2
Issuance of shares to employees under ESPP Plan		2
Net Loss
Ending balance	452,174	433,614
Accumulated Deficit [Member]
Beginning balance	(410,738)	(384,269)
Stock-based compensation
Advaxis public offerings, net of offering costs
Warrant exercises
Issuance of shares to employees under ESPP Plan
Net Loss	(3,977)	(7,857)
Ending balance	$ (414,715)	$ (392,126)

XML 69 R58.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Oct. 31, 2020
Common stock warrant liability, warrants exercisable	$ 44	$ 17
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 44	$ 17

XML 70 R59.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Jan. 31, 2021	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 0.372

XML 71 R60.htm IDEA: XBRL DOCUMENT

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Beginning balance	$ 17
Warrant exercises	2,586	$ 2
Ending Balance	44
Warrant Liability [Member]
Beginning balance	17
Warrant exercises
Change in fair value	27
Ending Balance	$ 44

XML 72 R61.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($) $ in Thousands		3 Months Ended
	Feb. 28, 2021	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Number of warrants exercised		8,341,558	7,390,000	398,226
Proceeds from warrants exercise		$ 2,586
Subsequent Event [Member] \| November 2020 Offering [Member]
Number of warrants exercised	3,300,000
Proceeds from warrants exercise	$ 1,200

EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965T&UL4$L! A0#% @ M#D!P4G)0G.5I @ ! 8 !D ("!=M< 'AL+W=O(P(<" " !@ &0 M @($6V@ >&PO=V]R:W-H965T&UL4$L! A0#% @ #D!P4H/?:GX2 @ MG00 !D ("!KM\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #D!P4O\%ID5J @ > 8 !D M ("!8N< 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ #D!P4L(><=^< @ 9 @ !D ("!>?0 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #D!P M4J59SMB; @ ? < !D ("!MOP 'AL+W=O&POL! 0!?) &@ M @ '&!P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" .0'!2UDS DN ! #C(P $P @ '_"0$ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 10!% -H2 0# $ ! end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 96 325 1 false 35 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advaxis.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://advaxis.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://advaxis.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://advaxis.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statement of Cash Flows (Unaudited) Sheet http://advaxis.com/role/StatementOfCashFlows Condensed Statement of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Nature of Operations Sheet http://advaxis.com/role/NatureOfOperations Nature of Operations Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of Significant Accounting Policies and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Property and Equipment Sheet http://advaxis.com/role/PropertyAndEquipment Property and Equipment Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://advaxis.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Expenses Sheet http://advaxis.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Common Stock Purchase Warrants and Warrant Liability Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability Common Stock Purchase Warrants and Warrant Liability Notes 11 false false R12.htm 00000012 - Disclosure - Share Based Compensation Sheet http://advaxis.com/role/ShareBasedCompensation Share Based Compensation Notes 12 false false R13.htm 00000013 - Disclosure - Collaboration and Licensing Agreements Sheet http://advaxis.com/role/CollaborationAndLicensingAgreements Collaboration and Licensing Agreements Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://advaxis.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://advaxis.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders' Equity Sheet http://advaxis.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 00000017 - Disclosure - Fair Value Sheet http://advaxis.com/role/FairValue Fair Value Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://advaxis.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Policies) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of Significant Accounting Policies and Basis of Presentation (Policies) Policies http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Tables) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of Significant Accounting Policies and Basis of Presentation (Tables) Tables http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://advaxis.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://advaxis.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Tables) Sheet http://advaxis.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://advaxis.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://advaxis.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://advaxis.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Tables) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables Common Stock Purchase Warrants and Warrant Liability (Tables) Tables http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability 24 false false R25.htm 00000025 - Disclosure - Share Based Compensation (Tables) Sheet http://advaxis.com/role/ShareBasedCompensationTables Share Based Compensation (Tables) Tables http://advaxis.com/role/ShareBasedCompensation 25 false false R26.htm 00000026 - Disclosure - Leases (Tables) Sheet http://advaxis.com/role/LeasesTables Leases (Tables) Tables http://advaxis.com/role/Leases 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity (Tables) Sheet http://advaxis.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://advaxis.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - Fair Value (Tables) Sheet http://advaxis.com/role/FairValueTables Fair Value (Tables) Tables http://advaxis.com/role/FairValue 28 false false R29.htm 00000029 - Disclosure - Nature of Operations (Details Narrative) Sheet http://advaxis.com/role/NatureOfOperationsDetailsNarrative Nature of Operations (Details Narrative) Details http://advaxis.com/role/NatureOfOperations 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) Details http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 30 false false R31.htm 00000031 - Disclosure - Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation-ScheduleOfAnti-dilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss Per Share (Details) Details 31 false false R32.htm 00000032 - Disclosure - Property and Equipment (Details Narrative) Sheet http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://advaxis.com/role/PropertyAndEquipmentTables 32 false false R33.htm 00000033 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://advaxis.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 33 false false R34.htm 00000034 - Disclosure - Intangible Assets (Details Narrative) Sheet http://advaxis.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://advaxis.com/role/IntangibleAssetsTables 34 false false R35.htm 00000035 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://advaxis.com/role/IntangibleAssets-SummaryOfIntangibleAssetsDetails Intangible Assets - Summary of Intangible Assets (Details) Details 35 false false R36.htm 00000036 - Disclosure - Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) Sheet http://advaxis.com/role/IntangibleAssets-ScheduleOfCarryingValueOfIntangibleAssetsDetails Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) Details 36 false false R37.htm 00000037 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://advaxis.com/role/AccruedExpenses-SummaryOfAccruedExpensesDetails Accrued Expenses - Summary of Accrued Expenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Common Stock Purchase Warrants and Warrant Liability (Details Narrative) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative Common Stock Purchase Warrants and Warrant Liability (Details Narrative) Details http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables 38 false false R39.htm 00000039 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfOutstandingWarrantsDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfWarrantsActivityDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) Details 40 false false R41.htm 00000041 - Disclosure - Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability-ScheduleOfAssumptionsUsedInWarrantLiabilityDetails Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) Details 41 false false R42.htm 00000042 - Disclosure - Share Based Compensation (Details Narrative) Sheet http://advaxis.com/role/ShareBasedCompensationDetailsNarrative Share Based Compensation (Details Narrative) Details http://advaxis.com/role/ShareBasedCompensationTables 42 false false R43.htm 00000043 - Disclosure - Share Based Compensation - Summary of Share Based Compensation Expense (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfShareBasedCompensationExpenseDetails Share Based Compensation - Summary of Share Based Compensation Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - Share Based Compensation - Summary of RSU Activity and Related Information (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfRsuActivityAndRelatedInformationDetails Share Based Compensation - Summary of RSU Activity and Related Information (Details) Details 44 false false R45.htm 00000045 - Disclosure - Share Based Compensation - Summary of Changes in Stock Option Plan (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfChangesInStockOptionPlanDetails Share Based Compensation - Summary of Changes in Stock Option Plan (Details) Details 45 false false R46.htm 00000046 - Disclosure - Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfOutstandingAndExercisableOptionsDetails Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) Details 46 false false R47.htm 00000047 - Disclosure - Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) Sheet http://advaxis.com/role/ShareBasedCompensation-SummaryOfFairValueOfStockOptionsGrantedOfBsmDetails Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) Details 47 false false R48.htm 00000048 - Disclosure - Collaboration and Licensing Agreements (Details Narrative) Sheet http://advaxis.com/role/CollaborationAndLicensingAgreementsDetailsNarrative Collaboration and Licensing Agreements (Details Narrative) Details http://advaxis.com/role/CollaborationAndLicensingAgreements 48 false false R49.htm 00000049 - Disclosure - Leases (Details Narrative) Sheet http://advaxis.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://advaxis.com/role/LeasesTables 49 false false R50.htm 00000050 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) Details 50 false false R51.htm 00000051 - Disclosure - Leases - Schedule of Lease Expenses (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfLeaseExpensesDetails Leases - Schedule of Lease Expenses (Details) Details 51 false false R52.htm 00000052 - Disclosure - Leases - Schedule of Other Information Related to Leases (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfOtherInformationRelatedToLeasesDetails Leases - Schedule of Other Information Related to Leases (Details) Details 52 false false R53.htm 00000053 - Disclosure - Leases - Schedule of Cash Flow Information Related to Leases (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfCashFlowInformationRelatedToLeasesDetails Leases - Schedule of Cash Flow Information Related to Leases (Details) Details 53 false false R54.htm 00000054 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) Details 54 false false R55.htm 00000055 - Disclosure - Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) Sheet http://advaxis.com/role/Leases-ScheduleOfFutureMinimumPaymentsUnderOperatingLeaseDetails Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) Details 55 false false R56.htm 00000056 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://advaxis.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://advaxis.com/role/StockholdersEquityTables 56 false false R57.htm 00000057 - Disclosure - Stockholders' Equity - Summary of Stockholders Equity (Details) Sheet http://advaxis.com/role/StockholdersEquity-SummaryOfStockholdersEquityDetails Stockholders' Equity - Summary of Stockholders Equity (Details) Details 57 false false R58.htm 00000058 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://advaxis.com/role/FairValue-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 58 false false R59.htm 00000059 - Disclosure - Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) Sheet http://advaxis.com/role/FairValue-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) Details 59 false false R60.htm 00000060 - Disclosure - Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Sheet http://advaxis.com/role/FairValue-ScheduleOfChangesInFairValueOfWarrantLiabilitiesDetails Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) Details 60 false false R61.htm 00000061 - Disclosure - Subsequent Events (Details Narrative) Sheet http://advaxis.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://advaxis.com/role/SubsequentEvents 61 false false All Reports Book All Reports adxs-20200131.xml adxs-20200131.xsd adxs-20200131_cal.xml adxs-20200131_def.xml adxs-20200131_lab.xml adxs-20200131_pre.xml http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 78 0001493152-21-006062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-006062-xbrl.zip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�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ᡇ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�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end